[Trading Trend] RedEnvia withdraws preliminary listing review amid stricter exchange thresholds... Largest shareholder changes amid trading at 50 billion won range in OTC market

Bio venture company RedEnvia, which is developing the first medical treatment for Calcific Aortic Valve Disease (CAVD), withdrew its preliminary review for KOSDAQ listing in the first half of last year. Although it failed to cross the listing threshold, it is known that it is currently being steadily traded in the over-the-counter (OTC) market at a corporate value in the mid-to-late 50 billion won range. Amidst this, attention is focused on the direction of its financial structure and new drug pipeline along with a change in its largest shareholder.

Stricter Exchange Review Stance... Voluntary Withdrawal of Preliminary Listing Review 6 Months After Request

RedEnvia passed the technology assessment in February 2024 by receiving A and BBB grades from professional evaluation agencies (NICE D&B and Korea Enterprise Data), respectively. Afterward, following a stock split and a pre-IPO (pre-listing equity investment), the company submitted a request for preliminary review for KOSDAQ listing to the Korea Exchange in August of the same year, beginning the listing process in earnest.

However, the review was prolonged as the Korea Exchange's stance on technology special listing reviews became highly conservative and strict in the aftermath of the so-called 'Fadu incident'. Differences of opinion arose during the exchange's rigorous verification of business feasibility, marketability, and the possibility of quantitative evaluation during the preliminary review period. Ultimately, determining that it would be difficult to receive a proper valuation, RedEnvia voluntarily withdrew the preliminary review as of February 14, 2025, six months after the request.

[Source: RedEnvia Website]

Core Pipeline Cruising Smoothly... Building a Two-Track Business Model

Apart from the listing delay, clinical trials are cruising smoothly. The company is focusing on a drug repositioning strategy based on Dong-A ST's DPP-4 inhibitor class diabetes treatment, 'Evogliptin (Suganon)'. The core pipeline, 'RNV-1001', targets Calcific Aortic Valve Disease, for which there are currently no pharmacological treatments, and is undergoing global Phase 2b/3 clinical trials involving 867 patients across 28 hospitals in North America (the US and Canada). In addition, as a follow-up pipeline, the company has received approval for and is conducting a domestic exploratory Phase 2 clinical trial for 'RNV-1004', a complex mechanism-based treatment. The company is materializing its business model by pushing for direct commercialization in the North American market while aiming for out-licensing in other regions (Europe, Asia, etc.).

Financial Limitations of a Typical Early-Stage Biotech and Alternative Fundraising

RedEnvia, which is currently in the research and development stage without its own operating revenue, is showing the financial limitations of a typical early-stage bio company. Due to continuous research and development expenses, net losses have accumulated, resulting in an accumulated deficit of 69.6 billion won based on the 2025 financial settlement, and total equity stands at negative (-) 6.384 billion won, placing the company in a state of complete capital impairment. The external auditor raised a 'significant doubt about its ability to continue as a going concern' based on the large net loss and the situation where current liabilities exceed current assets.

As securing large-scale funding through a listing was delayed, the company infused funds through alternative methods such as the sale of old shares. For example, Ilsung IS joined as the second-largest shareholder by securing a 13.88% stake by acquiring a portion of the treasury stock that RedEnvia had acquired from its existing largest shareholder for 2 billion won, through which RedEnvia partially covered its global clinical trial costs.

Governance Reorganization: Largest Shareholder Changes from BioEnvia Co., Ltd. to Dong-A ST Co., Ltd.

A major change also occurred in the governance structure as the delay in the initial public offering (IPO) schedule and funding issues intertwined. On April 2, 2025, BioEnvia Co., Ltd., the former largest shareholder, disposed of its common stock through a substitute payment (payment in kind) to repay loans and accrued income. During this process, Dong-A ST Co., Ltd. newly secured the position of RedEnvia's largest shareholder. Market attention is focused on whether RedEnvia, having passed the hurdle of a failed listing and welcoming a strong new largest shareholder, can resolve its financial uncertainties and successfully conclude its late-stage clinical trials in North America.